Protective effects of lactoferrin chimera and bovine lactoferrin in a mouse model of enterohaemorrhagic Escherichia coli O157:H7 infection

Biochem Cell Biol. 2012 Jun;90(3):405-11. doi: 10.1139/o11-089. Epub 2012 Feb 14.

Abstract

Mice orally infected with enterohaemorrhagic Escherichia coli (EHEC) O157:H7 were used to evaluate the activity of bovine lactoferrin (bLF) and the synthetic peptide LFchimera. Groups of BALB/c mice inoculated intragastrically with EHEC O157:H7 showed chronic intestinal infection with the pathogen that persisted over 6 days and resulted in a high mortality rate (90%). LFchimera and kanamycin significantly decreased (40%) this mortality rate (P = 0.028). On the other hand, although mice administered with bLF showed an important reduction in mortality (50%), this was not statistically significant (P = 0.070). In infected and untreated mice, severe tubular necrosis, glomerular lesions, and moderate intratubular hyaline casts were found in the kidney. However, in the bLF and LFchimera groups we found a reduction in the damage and a substantial decrease in the bacterial concentration excreted in feces 48 h after infection. Furthermore, sepsis caused by EHEC was reduced by the treatments, evidenced by the fact that bacteria were not detected in the kidney or liver 72 h after infection. The results suggest the bLF and LFchimera could have potential as therapeutics in EHEC infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Antimicrobial Cationic Peptides / pharmacology*
  • Antimicrobial Cationic Peptides / therapeutic use
  • Bacteremia / drug therapy*
  • Bacteremia / microbiology
  • Cattle
  • Drug Therapy, Combination
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / microbiology
  • Escherichia coli O157 / drug effects*
  • Feces / microbiology
  • Intestines / microbiology
  • Intestines / pathology
  • Kanamycin / pharmacology*
  • Kanamycin / therapeutic use
  • Kidney / microbiology
  • Kidney / pathology
  • Lactoferrin / pharmacology*
  • Lactoferrin / therapeutic use
  • Liver / microbiology
  • Male
  • Mice
  • Mice, Inbred BALB C

Substances

  • Anti-Bacterial Agents
  • Antimicrobial Cationic Peptides
  • LFchimera peptide
  • Kanamycin
  • Lactoferrin